LTR Pharma has officially debuted on the Australian Securities Exchange (ASX) under ticker code LTP.
Our foremost priority is to execute a bioequivalence trial of SPONTAN® to support expedited regulatory approvals, and to market and sell SPONTAN in the United States and Australia, first.
We have a highly experienced team of pharmaceutical developers and commercialisation experts driving this program forward – and valued investors backing us too.
Successful phase I human proof of concept study now complete. SPONTAN® has shown to be six times faster than oral PDE5 inhibitors.
On track to register the first PDE5 inhibitor nasal spray, in a market estimated to reach US$6.0B in 2028.
Progressing to bioequivalence study, with expedited regulatory filings in the United States and Australia within 1-2 years.
View our Shareholder Communications summary here
View our Corporate Directory here
The Australian has published a Special Report titled ‘LTR Pharma completes study milestone for SPONTAN ED treatment’, outlining that LTR Pharma has completed a key
In the third episode of our Conversation Series, Sexologist and Nurse Practitioner, Melissa Hadley Barrett reveals the surprising lifestyle factors that significantly impact men’s sexual
LTR Pharma is pleased to announce that Clinical Associate Professor Darren Katz, a renowned urological surgeon and Medical Director of Men’s Health Melbourne, has joined
9/204 Alice Street, Brisbane QLD 4000
Phone: 1800 519 711